Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma.

Olivia Desty SabungaCahyono KaelanAndi Alfian ZainuddinNi Ketut SungowatiMuhammad Husni CangaraUpik Miskad

Published in: Asian Pacific journal of cancer prevention : APJCP (2022)

The IDH1-R132H and CD133 can provide predictive value on treatment success, disease prognosis, recurrence and can be considered as target combination therapy with chemotherapy.

Keyphrases

combination therapy
wild type
cancer stem cells
low grade
poor prognosis
nk cells
high grade
binding protein
free survival
long non coding rna
replacement therapy